Svedlund Eriksson, Elin https://orcid.org/0009-0006-0169-6929
Lantero Rodriguez, Marta https://orcid.org/0000-0002-9912-6716
Halvorsen, Bente https://orcid.org/0000-0002-6529-6485
Johansson, Inger https://orcid.org/0009-0008-3579-9031
Mårtensson, Anna K. F. https://orcid.org/0000-0002-8786-4965
Wilhelmson, Anna S. https://orcid.org/0000-0003-0640-0251
Huse, Camilla https://orcid.org/0000-0002-7694-5196
Ueland, Thor
Aukrust, Pål https://orcid.org/0000-0003-0919-836X
Broch, Kaspar https://orcid.org/0000-0003-4316-805X
Gullestad, Lars
Amundsen, Brage Høyem https://orcid.org/0000-0001-7914-7395
Andersen, Geir Øystein https://orcid.org/0000-0003-1578-6440
Karlsson, Mikael C. I. https://orcid.org/0000-0001-5582-614X
Hagberg Thulin, Malin https://orcid.org/0000-0002-8673-1247
Camponeschi, Alessandro https://orcid.org/0000-0002-6472-2438
Trompet, Dana https://orcid.org/0000-0001-9472-6184
Hammarsten, Ola
Redfors, Björn
Borén, Jan
Omerovic, Elmir
Levin, Malin C.
Chagin, Andrei S. https://orcid.org/0000-0002-2696-5850
Dahl, Tuva B. https://orcid.org/0000-0001-7818-9411
Tivesten, Åsa https://orcid.org/0000-0002-8318-0486
Article History
Received: 14 March 2024
Accepted: 13 January 2025
First Online: 5 February 2025
Competing interests
: K.B. has received lecture fees from Amgen, AstraZeneca, Boehringer, Novartis, NovoNordisk, Pharmacosmos, Pfizer, and consultant fees from AstraZeneca, Boehringer, Pharmacosmos, and Pfizer. L.G. has received lecture fees from AstraZeneca, Boehringer Ingelheim, Novartis, and Amgen. The remaining authors declare no competing interests.